Lungenembolie

In diesem Übersichtsartikel werden aktuelle Empfehlungen internationaler Leitlinien sowie die neuesten Erkenntnisse zur Diagnose, Risikostratifizierung, medikamentösen und kathetergestützten Reperfusionsbehandlung sowie der initialen und langfristigen Antikoagulation unter Berücksichtigung des individuellen Rezidiv- und Blutungsrisikos bei Patienten mit Lungenembolie zusammengefasst, durch klinische Fallbeispiele begleitet und kritisch diskutiert.

Abstract

Pulmonary embolism (PE) is a life-threatening disease and the third most frequent cardiovascular cause of death after stroke and myocardial infarction. The annual incidence is increasing (in Germany from 85 cases per 100000 population in the year 2005 to 109 cases per 100000 population in the year 2015). The individual risk for PE-related complications and death increases with the number of comorbidities and severity of right ventricular dysfunction. Using clinical, laboratory and imaging parameters, patients with PE can be stratified to four risk classes (high, intermediate-high, intermediate-low and low risk). This risk stratification has concrete therapeutic consequences ranging from out-of-hospital treatment of low-risk patients to reperfusion treatment of (intermediate)-high-risk patients. For haemodynamically unstable patients, treatment decision should preferably be made in interdisciplinary “Pulmonary Embolism Response Teams” (PERT). Due to their comparable efficacy and preferable safety profile compared to vitamin-K antagonists (VKAs), non-vitamin K-dependent oral anticoagulants (NOACs) are increasingly considered the treatment of choice for initial and prolonged anticoagulation of patients with pulmonary embolism. Use of low molecular weight heparins (LMWHs) is recommended for PE patients with cancer; however, recent studies indicate that treatment with factor Xa-inhibitors may be effective and safe (in patients without gastrointestinal cancer). Only prolonged anticoagulation (in reduced dosage) will ensure reduction of VTE recurrence and should thus be considered for all patients with unprovoked events.

Kernaussagen

• Die akute Lungenembolie stellt nach dem Myokardinfarkt und dem Schlaganfall die dritthäufigste kardiovaskuläre Todesursache dar.

• Die Inzidenz einer Lungenembolie ist steigend (in Deutschlang von 85 pro 100 000 Einwohner im Jahr 2005 auf 109 pro 100 000 Einwohner im Jahr 2015).

• Das individuelle Risiko für mit Lungenembolie assoziierte Komplikationen und Letalität steigt mit der Anzahl von Begleiterkrankungen und dem Ausmaß der rechtsventrikulären Dysfunktion.

• Mittels klinischer, laborchemischer und bildgebender Parameter können Patienten mit Lungenembolie in 4 Risikoklassen eingeteilt werden (hoch, intermediär-hoch, intermediär-niedrig, niedrig).

• Die Therapie von Patienten mit Lungenembolie richtet sich nach dem individuellen Risikoprofil und reicht von einer ambulanten Behandlung bis hin zur rekanalisierenden Therapie mit intensivmedizinischem Monitoring.

• Zur ambulanten Therapie wird eine orale Antikoagulation mit einem NOAK (Apixaban, Dabigatran, Edoxaban oder Rivaroxaban) empfohlen und den Vitamin K-Antagonisten vorgezogen.

• Therapieentscheidungen für hämodynamisch instabile Lungenemboliepatienten sollten im interdisziplinären Expertenteam (Pulmonary Embolism Response Team [PERT]) getroffen werden.

• Für Lungenemboliepatienten mit Krebserkrankung kann eine therapeutische Antikoagulation mit NMH (mindestens 3–6 Monate) durchgeführt werden, aber auch die Anwendung von Faktor Xa-Inhibitoren ist bei Krebspatienten (ohne gastrointestinale Tumoren) effektiv und sicher.

• Für die Sekundärprophylaxe von Lungenembolien und venösen Thromboembolie (VTE) ist es entscheidend, ob ein niedriges oder eine hohes Rezidivrisiko vorliegt. Ein wirksamer Schutz vor einem VTE-Rezidiv ist nur durch eine Fortführung der Antikoagulation (auf unbestimmte Dauer) gegeben und sollte für alle Patienten mit einem hohen Rezidivrisiko (Antiphospholipid-Syndrom, Krebserkrankung, VTE in der Anamnese) erwogen werden.

Schlüsselwörter

Lungenembolie - Risikostratifizierung - Thrombolyse - Antikoagulation - Dyspnoe

Keywords

pulmonary embolism - risk stratification - thrombolysis - anticoagulation

Publikationsverlauf

Artikel online veröffentlicht:
18. Oktober 2021

• Literatur

• 1 Raskob GE, Angchaisuksiri P, Blanco AN. et al. Thrombosis: a major contributor to global disease burden. Arterioscler Thrombos Vasc Biol 2014; 34: 2363-2371
• 2 Keller K, Hobohm L, Ebner M. et al. Trends in Thrombolytic Treatment and Outcomes of Acute Pulmonary Embolism in Germany. Eur Heart J 2020; 41: 522-529
• 3 Barco S, Mahmoudpour SH, Valerio L. et al. Trends in mortality related to pulmonary embolism in the European Region, 2000–15: analysis of vital registration data from the WHO Mortality Database. Lancet Respir Med 2020; 8: 277-287
• 4 Vonk Noordegraaf A, Westerhof BE, Westerhof N. The Relationship Between the Right Ventricle and its Load in Pulmonary Hypertension. J Am Coll Cardiol 2017; 69: 236-243
• 5 Barco S, Ende-Verhaar YM, Becattini C. et al. Differential impact of syncope on the prognosis of patients with acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J 2018; 39: 4186-4195
• 6 Wood KE. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 2002; 121: 877-905
• 7 Konstantinides SV, Meyer G. The 2019 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism. Eur Heart J 2019; 40: 3453-3455
• 8 Hobohm L, Lankeit M. Lungenembolie. Dtsch Med Wochensch 2019; 144: 1286-1300
• 9 van der Hulle T, Cheung WY, Kooij S. et al. Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study. Lancet 2017; 390: 289-297
• 10 Murphy N, Broadhurst DI, Khashan AS. et al. Gestation-specific D-dimer reference ranges: a cross-sectional study. BJOG 2015; 122: 395-400
• 11 Righini M, Robert-Ebadi H, Elias A. et al. Diagnosis of Pulmonary Embolism During Pregnancy: A Multicenter Prospective Management Outcome Study. Ann Intern Med 2018; 169: 766-773
• 12 van der Pol LM, Tromeur C, Bistervels IM. et al. Pregnancy-Adapted YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism. N Engl J Med 2019; 380: 1139-1149
• 13 Hobohm L, Keller K, Valerio L. et al. Fatality rates and use of systemic thrombolysis in pregnant women with pulmonary embolism. ESC Heart Jailure 2020; 7: 2365-2372
• 14 van der Wall SJ, Hendriks SV, Huisman MV. et al. Home treatment of acute pulmonary embolism: state of the art in 2018. Curr Opin Pulm Med 2018; 24: 425-431
• 15 Barco S, Mahmoudpour SH, Planquette B. et al. Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary embolism: a systematic review and meta-analysis. Eur Heart J 2019; 40: 902-910
• 16 Barco S, Schmidtmann I, Ageno W. et al. Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. Eur Heart J 2020; 41: 509-518
• 17 Hobohm L, Anusic T, Konstantinides SV. et al. Ambulatory treatment of low-risk pulmonary embolism in fragile patients: a subgroup analysis of the multinational Home Treatment of Pulmonary Embolism (HoT-PE) Trial. Eur Respir J 2020; 56
• 18 Becattini C, Agnelli G, Germini F. et al. Computed tomography to assess risk of death in acute pulmonary embolism: a meta-analysis. Eur Respir J 2014; 43: 1678-1690
• 19 Rudski LG, Lai WW, Afilalo J. et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23: 685-713 , quiz 786–688
• 20 Lankeit M, Konstantinides S, Hellenkamp K. et al. Diagnostik und Therapie der akuten Lungenembolie. 2., neubearb. Aufl. UNI-MED Science; 2017
• 21 Stein PD, Matta F. Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused. Am J Med 2012; 125: 465-470
• 22 Kucher N, Boekstegers P, Muller OJ. et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 2014; 129: 479-486
• 23 Piazza G, Hohlfelder B, Jaff MR. et al. A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism: The SEATTLE II Study. JACC Cardiovasc Interv 2015; 8: 1382-1392
• 24 Tapson VF, Sterling K, Jones N. et al. A Randomized Trial of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Intermediate-Risk Pulmonary Embolism: The OPTALYSE PE Trial. JACC Cardiovasc Interv 2018; 11: 1401-1410
• 25 Hobohm L, Schmidt FP, Gori T. et al. In-hospital outcomes of catheter-directed thrombolysis in patients with pulmonary embolism. Eur Heart J Acute Cardiovasc Care 2020; 10: 258-264
• 26 Vedantham S, Goldhaber SZ, Julian JA. et al. Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. NEJM 2017; 377: 2240-2252
• 27 Lankeit M, Hobohm L, Konstantinides S. Akute Lungenembolie – Update 2018. Kardiologie Up2date 2018; 14: 67-81
• 28 van Es N, Coppens M, Schulman S. et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124: 1968-1975
• 29 Kearon C, Akl EA, Ornelas J. et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149: 315-352
• 30 Raskob GE, van Es N, Verhamme P. et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. NEJM 2018; 378: 615-624
• 31 Young AM, Marshall A, Thirlwall J. et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36: 2017-2023
• 32 Agnelli G, Becattini C, Meyer G. et al. Apixaban for the treatment of venous thromboembolism associated with cancer. NEJM 2020; 382: 1599-1607
• 33 Agnelli G, Prandoni P, Becattini C. et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003; 139: 19-25
• 34 Baglin T, Luddington R, Brown K. et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362: 523-526
• 35 Couturaud F, Sanchez O, Pernod G. et al. Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial. JAMA 2015; 314: 31-40
• 36 Klok FA, Kooiman J, Huisman MV. et al. Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review. Eur Respir J 2015; 45: 201-210
• 37 Klok FA, Barco S, Konstantinides SV. External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombos Haemostas 2017; 117: 1164-1170
• 38 Gomez-Outes A, Lecumberri R, Suarez-Gea ML. et al. Case fatality rates of recurrent thromboembolism and bleeding in patients receiving direct oral anticoagulants for the initial and extended treatment of venous thromboembolism: a systematic review. J Cardiovasc Pharmacol Ther 2015; 20: 490-500
• 39 Agnelli G, Buller HR, Cohen A. et al. Apixaban for extended treatment of venous thromboembolism. NEJM 2013; 368: 699-708
• 40 Weitz JI, Lensing AWA, Prins MH. et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. NEJM 2017; 376: 1211-1222